Anti-IGF2BP1 (IMP1) (Human) mAb

WB - 1 ug/mL for chemiluminescence detection system IP - 5 ug/500 uL of cell extract from 5 x 106 cells RIP - 15 ug/500 uL of cell extract from 1 x 107 cells

IGF2 mRNA-binding protein 1 (IMP1) localization is associated with motility, and the major functions of IMP1 are carried out by the phylogenetically conserved K homology (KH) domains. IMP1 can affect stability, localization, and translation of its target RNAs. Binding of IMP1 to the leader 3 mRNA in the 5?-untranslated region (UTR) of IGF2 inhibits translation from a leader 3 reporter mRNA. Aberrant IMP1 expression may interfere with c-myc regulation. In tumors, gains at 8q24 (c-myc locus) were observed to be more frequent than those at 17q21 (IMP1 locus). Furthermore, IMP1 expression was frequently detected in tumors, implying that the mechanism of activation is other than that of gene amplification.

1.0 mg/ml

Posttranscriptional regulation of gene expression is a ribonucleoprotein-driven process, which involves RNA binding proteins (RBPs) and non-coding RNAs that affect splicing, nuclear export, subcellular localization, mRNA decay and translation. The RNP Immunoprecipitation-Chip (RIP-Chip), RIP-Seq and RIP-RTPCR allow the identification of multiple RNA targets of RBPs globally and within the context of a cell extract. Antibodies specific to the RNA binding protein of interest are used to co-immunoprecipitate the RNA binding protein and the associated subset of mRNAs. The mRNA content is interrogated using standard microarray or sequencing technology. RIP-Certified Antibody is validated for use in RNP Immunoprecipitation (RIP) in conjunction with the RIP-Assay kit distributed from MBLI. Its ability to immunoprecipitate mRNAs and RBPs complex was confirmed by quantitative and qualitative analysis on NanoDrop, Bioanalyzer and RT-PCR or microarray.

200 ug IgG in 200 ul volume of PBS containing 50% glycerol, pH 7.2. No preservative is contained.

Human: 10642 Mouse: 140486

IGF2BP1 recombinant full-length

This antibody reacts with human IGF2BP1 (~63 kDa) on Western blotting, Immunoprecipitation and RNP Immunoprecipitation.

1 year

This antibody was purified from hybridoma (clone 6H6) supernatant using protein A agarose. This hybridoma was established by fusion of mouse myeloma cell P3U1 with C3H mouse lymphocyte immunized with full length of human IGF2BP1.

IGF2BP1/IMP1